A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02236611 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1036

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Umeclidinium
DRUG: Glycopyrronium

Sponsor

GlaxoSmithKline